Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own2.30% Shs Outstand348.40M Perf Week-10.21%
Market Cap9.10B Forward P/E2.50 EPS next Y10.46 Insider Trans0.00% Shs Float333.08M Perf Month-25.74%
Income-291.70M PEG- EPS next Q1.38 Inst Own66.80% Short Float5.05% Perf Quarter-68.85%
Sales10.45B P/S0.87 EPS this Y-133.00% Inst Trans20.17% Short Ratio0.50 Perf Half Y-71.31%
Book/sh16.97 P/B1.54 EPS next Y22.47% ROA-0.60% Target Price60.89 Perf Year-88.90%
Cash/sh1.71 P/C15.23 EPS next 5Y12.25% ROE-4.60% 52W Range23.55 - 263.81 Perf YTD-74.31%
Dividend- P/FCF4.80 EPS past 5Y4.40% ROI3.70% 52W High-90.10% Beta0.26
Dividend %- Quick Ratio0.80 Sales past 5Y54.60% Gross Margin75.30% 52W Low10.87% ATR2.40
Employees22000 Current Ratio1.00 Sales Q/Q23.10% Oper. Margin14.40% RSI (14)41.14 Volatility6.83% 9.25%
OptionableYes Debt/Eq5.26 EPS Q/Q-170.70% Profit Margin-2.80% Rel Volume0.66 Prev Close26.21
ShortableYes LT Debt/Eq5.12 EarningsJun 10 BMO Payout- Avg Volume33.74M Price26.11
Recom2.90 SMA20-13.61% SMA50-17.68% SMA200-75.70% Volume22,354,759 Change-0.38%
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Mar-16-16Reiterated Canaccord Genuity Hold $75 → $40
Mar-16-16Downgrade Nomura Buy → Neutral $175 → $60
Mar-16-16Downgrade CIBC Sector Perform → Sector Underperform
Mar-15-16Downgrade Piper Jaffray Neutral → Underweight
Mar-08-16Reiterated Mizuho Neutral $112 → $70
Mar-02-16Downgrade Canaccord Genuity Buy → Hold $125 → $75
Mar-01-16Downgrade RBC Capital Mkts Outperform → Sector Perform $194 → $85
Feb-29-16Downgrade TD Securities Buy → Hold
Feb-19-16Initiated Wells Fargo Underperform
Feb-16-16Initiated Rodman & Renshaw Buy $150
Jan-07-16Reiterated Mizuho Neutral $130 → $112
Jan-06-16Resumed Susquehanna Neutral $105
May-24-16 04:51PM  SEC raises concerns about Valeant's use of "Non-GAAP" measures Reuters
04:20PM  Billionaire Battleground: Valeant Pharmaceuticals Shares Are in Wall Street's Crosshairs at Motley Fool
03:34PM  SEC Asked Valeant to Change How It Reported Deal Costs, Tax at Bloomberg
02:25PM  The SEC is looking at Valeants potentially misleading accounting practices at MarketWatch
02:11PM  Valeant Pharmaceuticals: The SEC is 'Concerned' With Valeant's Accounting. Should You Be Too? at Barrons.com
11:56AM  Valeant to Evaluate Sales of Noncore Assets
10:59AM  One Reason Valeant (VRX) Stock is Down Today
10:21AM  Valeant Pharmaceuticals: It's Complicated at Barrons.com
08:23AM  Valeant Pharmaceuticals: New Documents Shed Light on the Philidor Fiasco at Motley Fool
May-23-16 04:10PM  The Social Media Index: Todays Market Sentiment Indicator
03:24PM  Taiwan ETF Bounces as New President Provides Clarity
02:47PM  GREK: Greece ETF Surges Thanks to Debt Relief
02:02PM  Bayers Monsanto Bid Lifts Agribusiness ETFs
11:48AM  Sequoia Fund Sets Portfolio Limits To Guard Against Valeant Redux at Barrons.com
11:15AM  Here's a Reason Why Valeant (VRX) Stock Is Down Today
10:58AM  Plucky Preferred ETFs for Portfolio Income
10:56AM  Valeant: Turning Over a New Guidance Leaf? at The Wall Street Journal
10:30AM  Valeant CEO Papa plans to lower debt by more than $1.5 billion in 2016 Reuters
10:29AM  Valeant CEO Papa plans to lower debt by more than $1.5 bln in 2016 Reuters
09:56AM  Why Are These Five Stocks in Spotlight on Monday? at Insider Monkey
09:42AM  Valeant's new CEO: 'Did we do that? Yes. Was it a mistake? Yes.'
09:36AM  Valeant New CEO Papa Sees Speed Bumps in Dermatology at Bloomberg
09:06AM  Morning Movers: Alcoa Jumps on Merrill Upgrade; Monsanto Climbs on Bayer Bid at Barrons.com
08:57AM  Valeant's new CEO Papa says there is a lot to work on
07:24AM  Valeant Gets Default Notice, Senior VP Resigns (VRX) at Investopedia
07:00AM  Painful Valeant Debacle Spurs Improvements at Sequoia at Morningstar
07:00AM  Bausch + Lomb Wins Walmart "Supplier of the Year" Award PR Newswire
07:00AM  Bausch + Lomb Wins Walmart "Supplier of the Year" Award CNW Group
05:55AM  A Rudderless Market
01:00AM  Valeant, Apple and Starbucks: Doug Kass' Views
May-21-16 09:00AM  Our Full Interview With Michael Van Biema
May-20-16 09:34PM  [$$] Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock at The Wall Street Journal
04:43PM  Valeant's senior VP Brian Stolz resigns at MarketWatch
04:20PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers
03:51PM  Sequoia Significantly Cut Valeant Stake, Fund Tells Investors
03:51PM  Sequoia Sharply Cuts Valeant Stake, Limits Position Sizes at Bloomberg
03:46PM  How Big Pharma Uses Charity Programs To Cover Drug Price Hikes
11:27AM  Specialty Pharma Stocks are CheapBut Only Some are Worth Buying at Barrons.com
09:43AM  Valeant Receives Default Notice, Accelerating Reporting Deadlines
09:29AM  Billionaire Bill Ackman Divulges Major Q1 Equity Moves at Insider Monkey
09:13AM  Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray
08:50AM  Valeant (VRX) Stock Slumps, Receives Notice of Default
08:40AM  The Other Canadian Drug Company That Has Pushed Up Drug Prices at Forbes
08:27AM  U.S. Futures Rally Premarket, Close Week on High Note
07:05AM  Valeant Falls After Questionable Bonus Payments (VRX) at Investopedia
07:00AM  3 Lessons From Hedge Funds Rise and (Partial) Fall at Morningstar
May-19-16 06:12PM  Valeant gets notice of default from bondholders Reuters -5.74%
06:11PM  Valeant Gets Notice of Default From Bondholders on Delayed 10-Q
06:11PM  Valeant Gets Default Notice on Late Quarterly Report at Bloomberg
06:00PM  Valeant Pharmaceuticals Receives Notice Of Default From Bondholders PR Newswire
06:00PM  Valeant Pharmaceuticals Receives Notice Of Default From Bondholders CNW Group
05:56PM  Valeant Erases Gains as Bonuses Concern Analysts
12:53PM  Here's a Reason Why Valeant (VRX) Stock Is Lower Today
12:45PM  Valeant Shares Under Pressure as Wells Fargo Cuts Estimates at TheStreet
09:25AM  9 Reasons Why the Worst May Not Be Over for Valeant Pharmaceuticals at Motley Fool
May-18-16 06:53PM  The Best Setup for New Traders
05:01PM  Michael Van Biema On Why Valeant Pharmaceuticals Failed
04:21PM  How Valeant Gave Itself Extra Time to File Delayed Financials
03:45PM  Valeant May Sell Some Assets to Reduce Debt, According to Report at TheStreet
03:15PM  Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference PR Newswire
03:15PM  Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference CNW Group
12:25PM  Valeant (VRX) Stock Down on Asset Sale Speculation at TheStreet
12:05PM  Wells Fargo Cuts Target on Valeant Citing Potentially 'Brazen' Executive Pay Packages
10:41AM  Valeant's Toxic Fire Sale at Bloomberg
09:15AM  Big Hedge Funds Washed Their Hands of These Companies in Q1 at Insider Monkey
07:03AM  Valeant Stock Rises on Possible Asset Sale (VRX) at Investopedia
01:00AM  Pharming Group: Interim Report on Financial Results for Q1 2016 PR Newswire
May-17-16 07:53PM  The short seller who took down Valeant went on TV to explain why he has invested in it, and ended up slamming a different stock +7.50%
07:06PM  Andrew Left Challenges Mallinckrodt to Do Proper Study of Its Main Drug at TheStreet
06:42PM  13F Summary For Q1
06:24PM  Valeant Gets Continued Boost After Ex-Bear Left Changes Mind at TheStreet
05:49PM  Valeant Rally Continues After Ex-Bear Declares Price Bottom at TheStreet
05:42PM  Mallinckrodt Is Robbing From the Healthcare System, Says Andrew Left at TheStreet
05:42PM  Mallinckrodt Is Robbing From the Health Care System, Says Andrew Left at TheStreet
05:21PM  Why Pandora Media, Southwestern Energy, and Valeant Pharmaceuticals Jumped Today at Motley Fool
05:21PM  The Stocks David Einhorn, Ray Dalio, and Bill Ackman Bought Last Quarter at Motley Fool
04:38PM  Valeant Said to Weigh Sale of Skin, Cancer Drugs Bloomberg
04:21PM  Citron's Andrew Left on Valeant and Pandora Bloomberg
04:13PM  Andrew Left: Valeant May See Higher Before It Sees Lower Bloomberg
03:58PM  Valeant Said to Weigh Sale of Skin, Cancer Drugs to Reduce Debt at Bloomberg
03:07PM  Home Depot earnings can't turn Dow around as stocks sell off Yahoo Finance
02:22PM  Why Valeant Bear Andrew Left Changed Tune on Stock at TheStreet
02:18PM  Mallinckrodt Is Robbing From the Healthcare System, Says Left at TheStreet
02:14PM  This Week In Valeant Pharmaceuticals (VRX) News Zacks
12:51PM  Citron's Andrew Left: Yes, I'm long Valeant, but... at CNBC
11:04AM  Billionaire Andreas Halvorsen's Viking Global Is Betting Over $6 Billion On FANG Stocks at Forbes
11:01AM  Canada Stocks Rise for 2nd Day as Health-Care, Commodities Gain at Bloomberg
09:52AM  2 Drug Stocks' Earnings to Watch this Week: VRX and XBIT Zacks
09:00AM  Trader's Notebook: Mining the Mining Stocks for Gold at TheStreet
12:12AM  [$$] Valeant Outlines Heart Drug Discounts After Heavy Scrutiny at The Wall Street Journal
May-16-16 10:34PM  Hedge Funds Abandon Ex-Darling Valeant and Other 13F Highlights Bloomberg
07:43PM  [$$] Valeant, Feeling Heat on Prices, to Offer Discounts on Two Heart Drugs at The Wall Street Journal
07:00PM  Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters PR Newswire
07:00PM  Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters CNW Group
06:59PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial EDGAR Online
06:02PM  Short seller sees possible 'bounce' in Valeant, shares climb 4% at CNBC
04:49PM  Regulatory filings show which Valeant investors exited in Q1 Reuters
04:47PM  Short Seller Andrew Left Says Valeants a Buy as Funds Exit at Bloomberg
04:47PM  Short Seller Andrew Left Says Valeants a Buy as Big Funds Exit Bloomberg
04:23PM  Valeant Shares Jump to the Upside at TheStreet
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM